Adaptimmune Therapeutics Plc Stock Price on March 26, 2024
| ADAP Stock | USD 0.72 0.01 1.37% |
Below is the normalized historical share price chart for Adaptimmune Therapeutics Plc extending back to May 06, 2015. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Adaptimmune Therapeutics stands at 0.72, as last reported on the 1st of December, with the highest price reaching 0.74 and the lowest price hitting 0.72 during the day.
If you're considering investing in Adaptimmune Stock, it is important to understand the factors that can impact its price. Adaptimmune Therapeutics secures Sharpe Ratio (or Efficiency) of -0.15, which signifies that the company had a -0.15% return per unit of standard deviation over the last 3 months. Adaptimmune Therapeutics Plc exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Adaptimmune Therapeutics' risk adjusted performance of (0.10), and Mean Deviation of 3.12 to double-check the risk estimate we provide.
At this time, Adaptimmune Therapeutics' Common Stock Total Equity is relatively stable compared to the past year. As of 12/01/2024, Common Stock is likely to grow to about 2 M, while Total Stockholder Equity is likely to drop slightly above 37.5 M. . At this time, Adaptimmune Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 12/01/2024, Price Earnings To Growth Ratio is likely to grow to 0.03, while Price To Operating Cash Flows Ratio is likely to drop (1.19). Adaptimmune Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of May 2015 | 200 Day MA 1.1049 | 50 Day MA 0.813 | Beta 2.247 |
Adaptimmune |
Sharpe Ratio = -0.1499
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADAP |
Estimated Market Risk
| 4.64 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Adaptimmune Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adaptimmune Therapeutics by adding Adaptimmune Therapeutics to a well-diversified portfolio.
Price Book 2.3055 | Enterprise Value Ebitda (1.71) | Price Sales 1.3114 | Shares Float 1 B | Wall Street Target Price 2.2667 |
Related Headline
Pieris Pharmaceuticals Headline on 26th of March 2024
Acquisition by Shane Olwill of 215819 shares of Pieris Pharm... by Shane Olwill
Filed transaction by Pieris Pharmaceuticals Officer Chief Development Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Adaptimmune Therapeutics Valuation on March 26, 2024
It is possible to determine the worth of Adaptimmune Therapeutics on a given historical date. On March 26, 2024 Adaptimmune was worth 1.45 at the beginning of the trading date compared to the closed value of 1.52. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Adaptimmune Therapeutics stock. Still, in general, we apply an absolute valuation method to find Adaptimmune Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adaptimmune Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Adaptimmune Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 1.46 | 1.56 | 1.42 | 1.44 | 1,175,504 | |
03/26/2024 | 1.45 | 1.57 | 1.38 | 1.52 | 1,194,956 |
| 1.55 | 1.63 | 1.47 | 1.58 | 1,184,494 |
| Backtest Adaptimmune Therapeutics | | | Adaptimmune Therapeutics History | | | Adaptimmune Therapeutics Valuation | Previous | Next |
Adaptimmune Therapeutics Trading Date Momentum on March 26, 2024
| On March 27 2024 Adaptimmune Therapeutics Plc was traded for 1.58 at the closing time. The top price for the day was 1.63 and the lowest listed price was 1.47 . The trading volume for the day was 1.2 M. The trading history from March 27, 2024 was a factor to the next trading day price gain. The overall trading delta against the next closing price was 3.95% . The overall trading delta against the current closing price is 8.55% . |
Adaptimmune Therapeutics Fundamentals Correlations and Trends
By evaluating Adaptimmune Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Adaptimmune Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Adaptimmune financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Adaptimmune Therapeutics Stock history
Adaptimmune Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Adaptimmune is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Adaptimmune Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Adaptimmune Therapeutics stock prices may prove useful in developing a viable investing in Adaptimmune Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 201.1 M | 129.5 M | |
| Net Loss | -148.9 M | -141.5 M |
Adaptimmune Therapeutics Quarterly Net Working Capital |
|
Adaptimmune Therapeutics Stock Technical Analysis
Adaptimmune Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Adaptimmune Therapeutics Period Price Range
Low | December 1, 2024
| High |
0.00 | 0.00 |
Adaptimmune Therapeutics Plc cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Adaptimmune Therapeutics December 1, 2024 Market Strength
Market strength indicators help investors to evaluate how Adaptimmune Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Adaptimmune Therapeutics shares will generate the highest return on investment. By undertsting and applying Adaptimmune Therapeutics stock market strength indicators, traders can identify Adaptimmune Therapeutics Plc entry and exit signals to maximize returns
Adaptimmune Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Adaptimmune Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Adaptimmune Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Adaptimmune to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.87) | |||
| Total Risk Alpha | (1.47) | |||
| Treynor Ratio | (0.51) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.